Objective: The aim of this study is to determine the effect of coenzyme Q (Q) on ob/ob mice treated or not with thiazolidinedione (TZD). Design and measurements: Ob/ob mice were treated with Q, Rosiglitazone or a combination of both molecules for 13 days; physical and metabolic parameters as well as oral glucose tolerance test were assessed. mRNA expression of genes of energy dissipation and storage were measured by real-time PCR. Results: Q treatment improved some metabolic parameters in ob/ob mice. Surprisingly, cotreatment with Rosiglitazone and Q improved metabolic parameters and prevented TZD increase in body weight and adiposity, mainly by increasing lipid oxidation in adipose tissue, reducing lipid synthesis and balancing adipokine gene expression. Conclusions: Our finding suggests that Rosiglitazone and coenzyme Q bitherapy could prevent the body weight gain associated with adipogenesis and could improve the clinical use of these compounds.
Introduction
Obesity and its associated comorbidities, such as type 2 diabetes and atherosclerosis, are currently reaching pandemic proportions, leading to increased investigations on adipose tissue biology. White adipose tissue (WAT) be involved in an interactive and complex network regulating numerous physiological functions such as: glucose homeostasis, lipid metabolism, inflammation, energy balance, reproduction and vascular functions. [1] [2] [3] Thus, lipoatrophy, as well as excessive WAT enlargement, lead to many organism dysfunctions including reduced lifespan. 4 These crucial roles are assumed by intense lipid metabolism and the controlled release of numerous signaling molecules and adipokines, among which adiponectin and tumor necrosis factor-a (TNFa) have key positive and negative functions, respectively, in the control of body weight, glucose and lipid metabolisms. [5] [6] [7] [8] [9] Thus, an excess of energy intake and/or a decrease in energy expenditure may reflect important dysfunctions in adipose tissue, for instance exacerbated fat storage and/or a deficit in oxidative metabolism. Recently, it has been shown that blocking the mitochondrial oxidative phosphorylation system (OXPHOS) increases lipid accumulation in adipocytes. 10 On the other hand, adipocytes isolated from obese mice have decreased O 2 consumption, 11, 12 indicating impairment in mitochondrial biology and physiology during obesity. Peroxisome proliferator-activated receptor-g (PPARg) is a master regulator of adipocyte differentiation and function. Thiazolidinediones (TZDs) are PPARg ligands commonly used for the treatment of type 2 diabetes. Despite the fact that they improve insulin sensitivity, their use is limited because of the adverse side effects observed in rodents and humans. Recent reviews point out the tolerability of these compounds in the treatment of type 2 diabetes, as monotherapy or in combination with other antidiabetic agents. 13, 14 Compared to other drugs, TZDs have two specific side effects: the increase in adiposity, mainly by increasing circulating fatty acid uptake and storage in adipose tissue, and fluid retention. Congestive heart failure, myocardial infarction and anemia are also characteristic of TZDs and other antidiabetic drugs, such as metformin or sulfonylureas. 13, 15, 16 It has been shown that TZDs also induced mitochondrial biogenesis and lipid oxidation in adipose tissue. As oxidative metabolism is highly dependent on a fine tuning of mitochondrial functions, all these data suggest an incomplete achievement of oxidative processes under PPARg ligand treatment.
Coenzyme Q (Q) is the only lipophilic, nonenzymatic antioxidant synthesized by human cells 17 and is present in all cellular membranes. Besides its antioxidant properties, Q is a key actor of mitochondrial function: (1) it is an obligatory member of the mitochondrial and extramitochondrial electron transfer systems; 18 (2) it regulates the mitochondrial permeability transition pore; (3) it is required for activation of the uncoupling proteins 19, 20 and (4) it regulates the physicochemical properties of membranes. 18 We have recently shown that Q content was increased in isolated adipocytes vs the stromal vascular fraction of adipose tissue and that its levels were strongly reduced in obese Zucker rats. 21 Furthermore, recent reports focused on redox control of metabolism 22, 23 and emphasized the role of mitochondria in adipocyte biology. [10] [11] [12] [24] [25] [26] [27] As Q supplementation has been extensively used in humans as a coadjuvant therapy in several myopathies, neurodegenerative disorders and cardiovascular complications [28] [29] [30] [31] [32] [33] resulting in the amelioration of oxidative metabolism and antioxidant protection in target tissues, we investigated the effect of Q alone or in coadministration with Rosiglitazone (R). ). Body weight and food intake were monitored daily. After 13 days of treatment, mice were killed by decapitation after CO 2 anesthesia, and blood samples were collected for immediate assays of glycemia levels. Plasma was frozen for further triglyceride (TG), nonesterified fatty acid (NEFA), lactate and insulin assays. Inguinal and epidydimal WATs, and interscapular brown adipose tissue (iBAT) were dissected, weighed and frozen for posterior analysis. Inguinal WAT samples were also analyzed for RNA content, and palmitic acid oxidation.
Methods

Chemicals
For the high-fat diet (HFD) experiments, lean C57BL/6 mice, were divided into two groups. To one group was given a standard diet (lean animals), and to the other a HFD (High Fat Bioserve, significance analysis of function and expression), both ad libitum. Body weight was monitored weekly for 14 weeks. Mice with a body weight corresponding to up to 4 Â s.d. of lean values were chosen for pharmacological studies. HFD mice were divided into two groups (control DMSO 10% (HF group) or 10 mg kg À1 Rosiglitazone and 10 mg kg À1 Q (RQ group)), and injected intraperitonealy daily for 20 days. Food intake and body weight were monitored daily. Mice were killed by decapitation after CO 2 anesthesia and samples were collected and processed as ob/ob mice samples.
Q determination by high-performance liquid chromatography Q measurements from tissues were performed as previously published.
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Whole-body densitometric analysis Densitometric analysis of fat and lean mass was performed using a PIXIMUS densitometer (LUNAR Corporation, Madison, WI, USA) as previously described. 35 Glucose tolerance test For the glucose tolerance test, food was withheld overnight before the intraperitoneal injection of glucose at 1 g of glucose per kg of body weight. Blood glucose levels were monitored using a glucose meter (Roche Applied Science, Lyon, France) from 2.5 ml of tail blood at À30, 0, 30, 60 and 90 min after glucose injection. Plasma insulin concentration was also measured 30 min after glucose injection in 10 ml of plasma from 20 ml of blood collected from the tip of the tail vein.
Real-time PCR
Total RNA from frozen tissues was extracted using the Extract-all solution (Eurobio). Complementary DNA was synthesized with the Super Script Reverse transcriptase and poly dT primers (Invitrogen, Cergy-Pontoise, France). The real-time PCR measurement of individual cDNAs was performed using SYBR green dye to measure duplex DNA formation with the Gene Amp 5700 (Applied Biosystem, Courtaboeuf, France) and normalized to the amount of cyclophilin cDNA. The following primers were used: acetylCoA carboxylase 1 (ACC1) forward GACTTGCAGAAGAAA TACGCCATA, reverse CTTGTATCCCTTGTAGGGATCTTCA; adiponectin forward TCCTGGAGAGAAGGGAGAGAAAG, reverse CCCTTCAGCTCCTGTCATTCC; cytochrome oxidase subunit IV (COIV) forward CCGACTGGAGCAGCCTTTC, reverse TCGGCGAAGCTCTCGTTAAA; cyclophilin forward GATGAGAACTTCATCCTAAAGCATACA, reverse TCAGTCTT GGCAGTGCAGATAAA; fatty acid synthase (FAS) forward TG CTCCCAGCTGCAGGC, reverse GCCCGGTAGCTCTGGGT GTA; carnitine-palmitoyl transferase 1, muscle isoform (M-CPT1) forward CCAAACGTCACTGCCTAAGCT, reverse GGC CGCACAGAATCCAAGT; phosphoenolpyruvate carboxykinase (PEPCK) forward GCCACAGCTGCTGCAGAA, reverse GAAG GGTCGCATGGCAAA; PPARg coactivator-1 (PGC-1) forward TGATGACAGTGAAGATGAAAGTGATAAAC, reverse GGCGA CACATCGAACAATGA; TNFa forward GCAGTCTGTGTCTG CTGGGAT, reverse CGCAGAACGGGATGAAGC; uncoupling protein-1 (UCP1) forward GACCGACGGCCTTTTTCAA, reverse AAAGCACACAAACATGATGACGTT.
Palmitic acid oxidation in iWAT
Palmitic acid oxidation rates were measured in iWAT homogenates as previously described.
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Statistical analyses Data are presented as mean ± s.e.m. Statgraphics Plus 5.1 was used for all statistical analysis. A one-way analysis of variance followed by Tukey's multiple comparison test was used to assess the statistical difference between groups. When appropriate, unpaired t-test was performed.
Results
Q treatment prevents R-induced body weight gain. The TZD compounds are PPARg ligands currently used for the treatment of type 2 diabetes, but one of the most important adverse side effects of these drugs is the increase in body weight partly because of increased adiposity. To test whether Q could prevent the R-induced body weight gain without affecting its beneficial effects on blood metabolite parameters we treated ob/ob mice with R, Q (Q) or a combination of both molecules (RQ). As expected and largely described, R-treated animals gained substantially much more weight than the other groups and displayed the highest food efficiency (Figure 1a ). Q-treated mice displayed the lowest body weight gain. Notably, RQ treatment prevented R-induced body weight gain (Figure 1a) , without affecting food intake ( Figure 1b ).
Q prevents adipose tissue weight gain As previously reported, R treatment induced a significant increase of total fat mass associated with an increase in iBAT and WATs (Table 1) . Q treatment had no significant effect on these parameters compared to control obese mice. In contrast, RQ coadministration prevented the R-induced increase of fat mass ( Table 1) . As in R-treated mice, RQ mice displayed an increase in iBAT compared to control mice. In contrast, the weight of WAT in RQ animals was not significantly different from this one of R mice. Moreover, liver weight was also lower in RQ mice compared to other groups.
Q enhances Rosiglitazone-mediated effects on glucose tolerance and on lipid profile in ob/ob mice As expected, Rosiglitazone normalized both blood glucose and insulin levels ( Table 2 ). Q alone slightly improved blood glucose and insulin levels but not enough to normalize them (Table 2) . RQ cotreatment was as efficient as R treatment. To find out whether Q could also affect the glucose-intolerance states that characterized the ob/ob mice, we performed the oral glucose tolerance test in treated animals. Glucose intolerance was clearly present in obese mice in comparison to lean mice (Figure 2a 
alone did not induce any beneficial effect, Rosiglitazone alone normalized glucose tolerance and the combination of Rosiglitazone with Q produced a highly significant improvement of this parameter. For lipid parameters, Q treatment induced a significant decrease compared to control obese mice. The RQ treatment was associated with the lowest levels in TG and NEFA levels ( Table 2) . Finally, Q as well as RQ treatments decreased lactate levels (Table 2) , indicating a putative improvement in whole-body oxidative metabolism.
Q prevents adipose tissue weight gain by increasing lipid oxidation
The weight of fat tissues demonstrated that RQ cotreatment prevented the Rosiglitazone-dependent increase in WAT Effects of Q in ob/ob mice MC Carmona et al weight in ob/ob mice. This led us to investigate the different parameters of lipid metabolism in adipose tissue of the different groups. Real-time PCR experiments revealed that R treatment enhanced the mRNA contents of lipogenic enzymes (FAS, and to a lesser extent ACC1) and glycerogenic enzyme PEPCK (Figure 3a) . This increase was completely abolished by RQ cotreatment. In addition, RQ-treated mice displayed a strong increase in mRNA content coding for different components of mitochondrial biogenesis, OXPHOS system and oxidative metabolism (Figure 3b) . Indeed, PGC-1 36 as well as the COIV 37 M-CPT1 and UCP-1 38 mRNAs, were all overexpressed in WAT from RQ-mice. Lipid oxidation in adipose tissue was higher in both R and Q treatments compared to control obese mice. This parameter was further increased in RQ mice (Figure 3c ). It is noteworthy that these changes were closely parallel with the changes in Q content of fat (Figure 3d ).
Q increase in adipose tissue corrects the unbalanced adiponectin and TNFa mRNA expression in iWAT of obese mice Considering the important role of adipokines on energy homeostasis and insulin sensitivity, we investigated the expression of two representative adipokines, adiponectin and TNFa, which are down and upregulated in obese mice, respectively. 8,9. As described, R treatment partially restored the balance between both cytokines (Figure 4 ). Q treatment specifically decreased the level of mRNA coding for TNFa. RQ treatment had the same effect on this cytokine and was more efficient in raising the expression of adiponectin mRNA than R treatment (Figure 4 ).
RQ bitherapy decreases body and WAT weights in a high-fat diet-induced model of obesity
To demonstrate that RQ bitherapy could be a new approach for the treatment of obesity, we assessed its effects in a Effects of Q in ob/ob mice MC Carmona et al nongenetic model of obesity (Figure 5a ). HFD mice treated with both molecules significantly lost weight without changes in food intake ( Figure 5b and data not shown, respectively). This net body weight reduction was also associated with a reduced WAT weight (Figure 5c ).
Discussion
Adipocyte hypertrophy, obesity and insulin resistance have been recently tied to mitochondrial dysfunction 10-12 Q may be a part of this network in adipocytes because of its special functions not only as antioxidant but also as regulator of mitochondrial metabolism. Data presented here demonstrate that Q can modulate adipose tissue development and function particularly under TZD treatment. Although we show that Q treatment has slight effects on lipid metabolism in ob/ob mice, its coadministration with TZD is associated with the improvement of TZD effects and the limitation of adipogenesis-dependent body weight gain. The benefit of Q supplementation on mitochondria and oxidative processes could be expected according to the key role of Q into the respiratory chain, but is mainly revealed when ob/ob mice are treated with TZD. The phenotype or RQtreated mice resembles, on many points, to a limited activation of PPARg, 39 in which the normalization of glucose metabolism and the controlled adipogenic processes are observed. In our study, the decrease in lactate levels, the improved lipid clearance and the increase in oxidative processes in white fat assessed by functional and molecular parameters could reflect an improvement of adipose tissue oxidative metabolism, which in turn may contribute to the normalization of glucose metabolism and blunted adipogenesis. However, the effect of Q on oxidative metabolism cannot explain all its effects. Indeed, contrary to the effects Q was supposed to have on PPARg activity, we also found that some other genes (that is, adiponectin) respond to RQ treatment with an increase in their expression instead of a decrease. This led us to consider other possibilities of action for Q. 47 Thus, the balance between positive and negative regulating signals on adiponectin gene promoter may contribute to the final adiponectin gene expression observed in the RQ-mice. Therefore, the correlation between Q content and adiponectin mRNA expression suggests a close link between both parameters that needs further investigation. Moreover, RQ treatment was associated with a strong downregulation of TNFa mRNA as Q treatment did. So, the RQ treatment restores the expression of adiponectin and TNFa mRNAs. The effects on respective protein contents and secretion would need to be investigated to definitively propose that these regulations could contribute, at least in part, to all metabolic benefits of RQ treatment. Finally, an increasing number of reports highlights the intertwined network between mitochondria, inflammation, oxidative stress and metabolic dysfunctions. 1, [22] [23] [24] [25] [26] Our data reveal that adipose Q can act favorably on some of these components and prevents the adipogenic side effects of Rosiglitazone. Interestingly, these effects are observed not only in the defective leptin signaling model (the ob/ob mice) but also in a nutrient-induced animal model of obesity (our high-fat model of diet-induced obesity; present results). However, as adverse adipogenic effect of TZD treatment is secondary compared to fluid retention and cardiovascular events, further and higher benefits of RQ biotherapy in preventing other and more serious TZDs adverse effects need to be finely evaluated. Indeed, Q treatment improves and/or prevents cardiovascular complications, such as chronic heart failure 28, 29, 48, 49 and myocardial infarction; 30, 50, 51 furthermore its usefulness in the treatment of some types of anemia has also been shown. 52, 53 In conclusion, as these adverse side effects limit the therapeutic indications of TZDs and their clinical usefulness, 39, 54, 55 our findings suggest that RQ bitherapy could overcome some of these limitations and extend the clinical use of these compounds.
